REFERENCE

바이오 산업의 미래를 그리는 기업, YntoAb

Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins

논문
작성자
인투앱 관리자
작성일
2023-01-09 18:25
조회
42

Biosensors and Bioelectronics 175 (2021) 112868 / H.-Y. Kim et al.

IF: 12.54(2021)
Doi: 10.1016/j.bios.2020.112868

Services used : Antibody service / ELI-lite package  👉[QUOTE]

Abstract
Coronavirus disease 2019 (COVID-19) is a newly emerged human infectious disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). In a global pandemic, development of a cheap, rapid, accurate,
and easy-to-use diagnostic test is necessary if we are to mount an immediate response to this emerging
threat. Here, we report the development of a specific lateral flow immunoassay (LFIA)-based biosensor for
COVID-19. We used phage display technology to generate four SARS-CoV-2 nucleocapsid protein (NP)-specific
single-chain variable fragment-crystallizable fragment (scFv-Fc) fusion antibodies. The scFv-Fc antibodies bind
specifically and with high affinity to the SARS-CoV-2 NP antigen, but not to NPs of other coronaviruses. Using
these scFv-Fc antibodies, we screened three diagnostic antibody pairs for use on a cellulose nanobead (CNB)-
based LFIA platform. The detection limits of the best scFv-Fc antibody pair, 12H1 as the capture probe and 12H8
as the CNB-conjugated detection probe, were 2 ng antigen protein and 2.5 × 104 pfu cultured virus. This LFIA
platform detected only SARS-CoV-2 NP, not NPs from MERS-CoV, SARS-CoV, or influenza H1N1. Thus, we have
successfully developed a SARS-CoV-2 NP-specific rapid diagnostic test, which is expected to be a simple and
rapid diagnostic test for COVID-19.

Keywords
COVID-19, SARS-CoV-2, Lateral flow immunoassay, Rapid diagnostic test, Antibody